Anavex Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-39.95	-46.38	-43	-47.51	-47.98	-37.91
Stock-Based Compensation	10.6	11.55	9.44	16.37	18.38	8.23
Other Adjustments	-	-	-	0.85	-	-
Changes in Accounts Payable	-1.93	-5.38	5.31	0.5	-0.91	0.75
Changes in Accrued Expenses	-4.81	-0.94	-2.46	1.35	0.33	2.3
Changes in Unearned Revenue	-0.02	-0.04	-0.08	0.47	-	0.44
Changes in Other Operating Activities	2.03	2.14	-0.02	0.19	5.95	-4.2
Operating Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Operating Cash Flow Growth	-	-	-	-	-	-
Issuance of Common Stock	2.24	12.14	11.98	29.65	22	158.79
Net Common Stock Issued (Repurchased)	2.24	12.14	11.98	29.65	22	158.79
Other Financing Activities	-	-2.71	-	-	-0.71	-5.55
Financing Cash Flow	45.05	9.43	11.98	29.65	21.29	153.24
Net Cash Flow	10.97	-29.61	-18.84	1.87	-2.95	122.86
Free Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.39	-0.46	-0.37	-0.35	-0.32	-0.44
Levered Free Cash Flow	-44.68	-50.59	-40.25	-45	-42.26	-38.35
Unlevered Free Cash Flow	-49.35	-55.62	-50.13	-53.26	-45.63	-42.71

SEC Filings: 10-K · 10-Q